Summary & Overview
HCPCS J1743: Injection, idursulfase, 1 mg
HCPCS Level II code J1743 designates a 1 mg unit of idursulfase, an enzyme replacement therapy administered by infusion in outpatient infusion centers or ambulatory clinics. This code matters nationally because biologic infusion drugs carry significant cost and utilization implications for specialty pharmacy, hospital outpatient departments, and commercial and public payers. Coverage, utilization controls, and prior authorization policies for high-cost infusible biologics are central to payer management and patient access.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the typical clinical setting for service delivery, and the national relevance for payers and providers. The publication also outlines expected benchmarks and policy topics readers can expect in the full analysis, including coverage criteria, utilization management practices, site-of-care considerations, and coding and billing implications for infusion drug administration.
Data not available in the input is noted where applicable. The focus is national in scope and intended for billing specialists, payers, and providers involved in specialty infusion services.
Billing Code Overview
HCPCS Level II code J1743 describes Injection, idursulfase, 1 mg. This code represents the billed drug unit for idursulfase, a recombinant enzyme replacement therapy used in infusion-based treatment regimens. Service type: drug administration / infusion medication. Typical site of service: hospital outpatient infusion center or ambulatory infusion clinic.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric person diagnosed with Hunter syndrome (mucopolysaccharidosis II) who requires enzyme replacement therapy with idursulfase. The patient arrives to an infusion center, hospital outpatient infusion suite, or specialized pediatric infusion clinic for scheduled intravenous administration. Prior to infusion, the nurse performs pre-infusion assessment (vitals, weight, review of recent labs and allergy history) and verifies the ordered dose in milligrams based on body weight. An intravenous line is established or an existing port is accessed. Premedication (antihistamine, corticosteroid) may be given for prior infusion reactions. Idursulfase (J1743, 1 mg per unit) is reconstituted and diluted per manufacturer instructions and administered via IV infusion over the recommended time with monitoring for infusion-related reactions. Documentation includes drug lot number, units administered, infusion start and stop times, patient tolerance, and any reactions. Post-infusion observation occurs per institutional protocol before discharge to home or inpatient unit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Primary service | When this infusion is the main service provided during the encounter |